Shannon D. Armbruster

Shannon D. Armbruster

Auto-generated profile, based on publicly available information

Shannon D. Armbruster

Department of OBGYN, Carilion Clinic, Roanoke, Virginia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
MMMichele L. McCarroll
Michele L. McCarroll
SAShannon Armbruster
Shannon Armbruster
RPRachael J. Pohle-Krauza
Rachael J. Pohle-Krauza
ALAmy M. Lyzen
Amy M. Lyzen
SMSarah Min
Sarah Min
VGVivian E. von Gruenigen
Vivian E. von Gruenigen

1 February 2014 in Gynecologic Oncology
Verified
Journal Article
Closed access
MMM.L. McCarroll
M.L. McCarroll
SAS. Armbruster
S. Armbruster
HFH.E. Frasure
H.E. Frasure
MGM D Gothard
M D Gothard
KGK.M. Gil
K.M. Gil
VGV.E. von Gruenigen
V.E. von Gruenigen

1 March 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
JBJennifer Bergstrom
Jennifer Bergstrom
AAAlessia Aloisi
Alessia Aloisi
SAShannon Armbruster
Shannon Armbruster
TYTing-Tai Yen
Ting-Tai Yen
JCJvan Casarin
Jvan Casarin
AFAmanda N. Fader
Amanda N. Fader

1 November 2018 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
RDRobert L. Dood
Robert L. Dood
YZYang Zhao
Yang Zhao
SAShannon D. Armbruster
Shannon D. Armbruster
RCRobert L. Coleman
Robert L. Coleman
STShelley Tworoger
Shelley Tworoger
KBKeith A. Baggerly
Keith A. Baggerly
Importance Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities and secondary cancers, overseen by oncologists, surgeons, and primary care physicians. Optimal timing and coordination of care, however, is unclear and often based on arbitrary 5-year cutoffs. Objective To determine high- and low-risk periods for all tumor types that could define when survivorship care might best be overseen by oncologists and when to transition to primary care physicians. Design, Setting, and Participants In this pan-cancer, longitudinal, observational study, excess mortality hazard, calculated as an annualized mortality risk above a baseline population, was plotted over time. The time this hazard took to stabilize defined a high-risk period. The percent morality elevation above age- and sex-matched controls in the latter low-risk period was reported as a mortality gap. The US population–based Surveillance, Epidemiology, and End Results database defined the cancer population, and the US Census life tables defined controls. Incident cases of patients with cancer were separated into tumor types based onInternational Classification of Diseases for Oncologydefinitions. Exposures Population-level data on incident cancer cases was compared with the general US population. Main Outcomes and Measures Overall mortality and cause of death were reported on observed cancer cases. Results A total of 2 317 185 patients (median age, 63 years; 49.8% female) with 66 primary tumor types were evaluated. High-risk surveillance period durations ranged from less than 1 year (breast, prostate, lip, ocular, and parathyroid cancers) up to 19 years (unspecified gastrointestinal cancers). The annualized mortality gap, representing the excess mortality in the stable period, ranged from a median 0.26% to 9.33% excess annual mortality (thyroid and hypopharyngeal cancer populations, respectively). Cluster analysis produced 6 risk cluster groups: group 1, with median survival of 16.2 (5th to 95th percentile range [PR], 10.7-40.2) years and median high-risk period of 2.5 (PR, 0-5.0) years; group 2, 8.3 (PR, 5.1-23.3) and 2.5 (PR, 4.0-8.0) years; group 3, 2.8 (PR, 1.4-3.7) and 7.0 (PR, 6.0-11.1) years; group 4, 1.6 (PR, 1.5-1.8) and 6.0 (PR, 5.1-11.4) years; group 5, 0.8 (PR, 0.5-1.2) and 0.8 (PR, 0.5-1.2) years; and group 6, 0.5 (PR, 0.4-0.8) and 12.0 (PR, 9.3-12.9) years, respectively. Subanalyses of selected tumor types in these groups revealed that stratifying on stage and histologic type can change the risk cluster and guidance for care. Conclusions and Relevance These findings indicate that a standardized 5-year surveillance period is inadequate for some cancers while excessive for others. High-risk cancers require the most resources with the longest high-risk period, highest persistent baseline mortality risk, and longest period of primary cancer mortality, all arguing for longer follow-up with an oncologist in these cancers.

1 December 2018 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
SAShannon Armbruster
Shannon Armbruster
RCRobert L. Coleman
Robert L. Coleman
JRJose Alejandro Rauh-Hain
Jose Alejandro Rauh-Hain

1 December 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
SAShannon D. Armbruster
Shannon D. Armbruster
JSJaejoon Song
Jaejoon Song
ABAndrea Bradford
Andrea Bradford
CCCindy L. Carmack
Cindy L. Carmack
KLKaren H. Lu
Karen H. Lu
KBKaren M. Basen-Engquist
Karen M. Basen-Engquist